Vosoritide was FDA approved in 2021, as an analog of C-type natriuretic peptide, capable of binding to the natriuretic peptide receptor type 2 and interrupting downstream signaling of the constitutively active FGFR3-mediated MAPK pathway present in achondroplasia. This evidence concerns the gene FGFR3 and achondroplasia.